Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$9.99 USD
-0.11 (-1.09%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $9.94 -0.05 (-0.50%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Rapt Therapeutics has a market cap of $167.01M, which represents its share price of $10.10 multiplied by its outstanding shares number of 16.54M. As a small-cap company, RAPT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RAPT 9.99 -0.11(-1.09%)
Will RAPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RAPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RAPT
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
RAPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for July 15th
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
New Strong Buy Stocks for July 15th
Other News for RAPT
RAPT Therapeutics (RAPT) Receives Neutral Rating Upgrade by JP Morgan | RAPT Stock News
JPMorgan Adjusts Rapt Therapeutics (RAPT) Rating with New Price Target
Rapt Therapeutics just upgraded at JPMorgan, here's why
RAPT Receives Outperform Rating with Promising Market Potential | RAPT Stock News
LifeSci starts Rapt Therapeutics at Outperform on potential for lead asset